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Abstract The cysteine-rich region (CRR) of the L2 integrin
subunit was replaced by that of L1 to give the chimera L2NV1.
L2NV1 can combine with KL to form a variant leukocyte-
function-associated antigen (LFA)-1 on COS cell surface,
suggesting that the specificity of the L2 interaction with KL
does not lie in the CRR. Unlike those expressing wild-type LFA-
1, COS cells expressing KLL2NV1 are constitutively active in
intercellular adhesion molecule (ICAM)-1 adhesion. These
results suggest that activation of LFA-1 involves the release of
an intramolecular constraint, which is maintained, in part, by the
authentic L2 CRR.
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1. Introduction
Integrins are a family of membrane glycoproteins which
mediate cell adhesion to extracellular matrix components
and to other cells [1,2]. Each integrin is a non-covalent heter-
odimer of an K and a L subunit. To date, 17 human K sub-
units and 8 human L subunits have been characterised and
over 20 KL heterodimers have been described. Both the K and
the L subunits of the integrins are type I membrane glycopro-
teins. Relatively little is known about their higher order struc-
tures. The K subunits are predicted to contain a L-propeller
structure formed by seven repeating elements [3]. Eight of the
17 characterized K subunits, including those of the four leu-
kocyte integrins, have an I-domain inserted between the sec-
ond and third repeating units of the predicted L-propeller. The
recombinant I-domains of the KL [4], KM [5,6] and K2 [7]
subunits have been crystallised and shown to assume a Ross-
mann fold. In addition, these recombinant I-domains have
been shown to bind the ligands of their respective parent in-
tegrins [8^12].
The integrin L subunits are linearly organised into an N-
terminal cysteine-rich region, a highly conserved region
(HCR), a middle connecting region, an extensive cysteine-
rich region (CRR), a transmembrane segment, and a cytoplas-
mic region of about 50 residues (Fig. 1). The exception is the
L4 subunit, which has an extensive cytoplasmic domain of
about 1000 residues, see CD104 entry in [13]. The HCR is
thought to contribute both to heterodimer formation and li-
gand binding. Most of the single residue mutations that cause
leukocyte adhesion de¢ciency (LAD), in which the patients
fail to express all members of the L2 integrin subfamily,
have been located in the HCR [14]. In addition, single residue
substitutions in the HCR constructed in the laboratory were
found either incapable of forming heterodimers or formed
heterodimers which were defective in ligand binding activities
[15,16]. The CRR is speculated to have regulatory functions
since epitopes of many antibodies which activate ligand bind-
ing, including KIM185 used in this study [17], have been
mapped to this region.
If the speci¢city of ligand binding lies in the K subunits,
what is the role of the L subunits? If the role of the L subunit
is mainly regulatory, how does it confer the regulation to the
K subunits? How the two subunits interact with each other is
therefore a relevant question in terms of understanding inte-
grin activation. A starting point to address this problem is to
ask how the integrin K and L subunits form heterodimers
only with certain counter-subunits, but not others. We focus
on the L2 subunit, which combines with the KL, KM, KX,
and KD subunits to form leukocyte-function-associated anti-
gen (LFA)-1 (KLL2, CD11a/CD18), Mac-1 (KML2, CD11b/
CD18), p150,95 (KXL2, CD11c/CD18), and the KDL2 antigen
[18,19]. The four K subunits are not known to combine with
any other L subunit and, conversely, the L2 subunit is not
known to interact with any K subunit outside this set of
four. In particular, leukocytes also express the L1 integrin
subunit (see CD29 entry in [13]), but the expression of the
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KL, KM, and KX subunits with L1 has not been detected.
Peripheral blood leukocytes express only low levels of KDL2
[19] and little is known about the capacity of KD to form
heterodimers with other L integrin subunits.
We have therefore constructed L2/L1 chimeric subunits and
studied their capacity to combine with the KL subunit and the
interaction of the resultant heterodimers with intercellular ad-
hesion molecule (ICAM)-1. We report here the study on the
chimera L2NV1, in which the CRR of the L2 subunit was
replaced by the corresponding region of L1 (Fig. 1). This
chimeric subunit can combine with the KL subunit to form
a variant LFA-1, which is constitutively active in binding
ICAM-1.
2. Materials and methods
The monoclonal antibodies (mAbs) MHM24 (anti-KL), H52 (anti-
L2), KIM185 (anti-L2), and OX33 (control) were previously described
[20,21]. MEM83 (anti-KL) was a gift from V. Horejsi (Academy of
Sciences of the Czech Republic, Prague, Czech Republic), YFC118
(anti-L2) and YTS191 (control) were gifts from S. Cobbold and H.
Waldmann (Sir William Dunn School of Pathology, Oxford, UK),
and mAb 24 (anti-CD11/CD18 heterodimers) was a gift from N.
Hogg (ICRF, London, UK). ICAM-1/Fc was prepared as described
[22].
The KL cDNA clone was reported previously [23]. The L1 (partial)
cDNA clones were screened from a HPBALL library [24] using
probes constructed by PCR based on the published sequences of L1
[25].
The original cDNA clone coding for the L2 integrin subunit, J8,
was in the PATX vector [26,27]. Three NcoI sites, one in the coding
region, and two in the 3P untranslated region, are found in the cDNA
of L2. The fragment from the internal SacII site to the 3P XhoI cloning
site was removed from J8 and replaced by a synthetic polylinker
containing the restriction enzyme sites for SacII, StuI, SpeI, SstI,
XbaI and XhoI to give J8.1SXp. The fragment from the same internal
SacII site to the ¢rst NcoI site in the 3P untranslated region of J8 was
blunt-ended at the NcoI site and inserted into the SacII and StuI site
of J8.1SXp to give J8.1N. In this manipulation the two NcoI sites in
the 3P untranslated region were removed. The entire insert containing
the entire coding region of L2 of J8.1N, a ClaI/SstI fragment, was
cloned into the same sites in the polylinker of pBluescript. The resul-
tant clone, J8.1E, has unique sites for XbaI, BamHI, EcoRI, NcoI and
SacII in the cDNA insert. An EcoRV site was introduced at the
extracellular/transmembrane junction of J8.1E by PCR using the
strategy of Horton et al. [28] to yield the variant clone J8.1EV. Frag-
ments encoding the CRR of L1 was obtained by PCR using 5P oligo-
nucleotides with an NcoI site and blunt-end 3P oligonucleotides. The
fragment was digested with NcoI and used to replace the NcoI/EcoRV
fragments of J8.1EV to yield the chimeric clone L2NV1. The chimeric
clones were veri¢ed by cDNA sequencing. The inserts of the L2 and
L2NV1 clones were removed with Asp718I and SpeI and cloned into
the Asp718I and XbaI sites of the expression vector pcDNA3 (Invi-
trogen).
cDNAs of the KL, L2 and L2NV1, in pcDNA3, were transfected
singly or in KL pairs into COS-7 cells by the DEAE-dextran method
[24]. Protocols for the harvesting of transfectants, the analysis of
LFA-1 expression by £ow cytometry and immunoprecipitation, and
the adhesion of transfectants to ICAM-1 coated microtiter plates were
described in Al-Shamkhani and Law [21].
3. Results
3.1. Expression of the KL, L2 and L2NV1 integrin subunits
on COS-7 cells
COS-7 cells were transfected with plasmids containing the
cDNA for integrins subunits either singly or in KL combina-
tions. Expression of the KL subunit was monitored by the
mAb MHM24 and the L2 and L2NV1 subunits by the
mAbs YFC118, H52 and KIM185 (Fig. 2). All three subunits
are expressed on COS-7 cells. In addition, whereas the epi-
topes of the three anti-L2 antibodies are expressed on the L2
transfectants, only the epitopes of YFC118 and H52, but not
that of KIM185, are expressed on the L2NV1 transfectants.
This is consistent with the mapping of the epitopes of
YFC118, H52, and KIM185 to the HCR [29], mid-region
[21] and CRR [17], respectively. The expression pro¢les of
the anti-L2 epitopes in the KLL2 and KLL2NV1 transfectants
are correspondingly similar to those of the L2 and L2NV1
transfectants. However, the expression of the MHM24 epitope
is signi¢cantly enhanced in the KL transfectants when com-
pared with the KL transfectants.
Monomeric and heterodimeric expression were analysed by
immunoprecipitation of the integrin subunits from surface-la-
belled cell lysates of the transfectants (Fig. 3). Only the L2 and
L2NV1 subunits were precipitated with H52 from the respec-
tive transfectants, con¢rming that they are expressed as
monomers on the cell surface without combining with endog-
enous K subunits from the COS cells. Similarly, only the KL
subunit is precipitated with MHM24 from the KL transfec-
tants. However, in addition to the KL subunit, the L2 and
L2NV1 subunits were also present in the immunoprecipitate
from the lysates of the KLL2 and KLL2NV1 transfectants,
respectively, with the KL-speci¢c mAb MHM24. These results
showed that the L2NV1 chimera can combine with the KL
subunit to form a variant form of LFA-1.
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Fig. 1. A: The regional organization of the L integrin subunits. The
locations of the 56 conserved cysteine residues in the extracellular
domain are indicated by vertical lines under the main diagram.
B: Alignment of the CRR of the L1 and L2 integrin subunits. Iden-
tical residues are indicated by (b) between the sequences; identical
conserved cysteine residues are marked by (M)s. The numbering
underneath is that of the human L2 sequence.
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3.2. Adhesion of COS-7 transfectants expressing wild-type
and variant LFA-1 to ICAM-1
COS-7 transfectants were studied for their adhesion to
ICAM-1 at di¡erent ligand densities (Fig. 4). The L2 and
L2NV1 transfectants were not adherent to ICAM-1 including
the L2 transfectants in the presence of the stimulatory mAb
KIM185. The KL transfectants can be stimulated to adhere to
ICAM-1 with the KL-speci¢c mAb MEM83. Transfectants
expressing wild-type LFA-1 also require activation for adhe-
sion to ICAM-1. However, this is not simply due to the more
e¡ective expression of the KL subunit since activation can also
be promoted with the L2-speci¢c mAb KIM185. The
KLL2NV1 transfectants adhere to ICAM-1 readily in the ab-
sence of activating mAbs, and adhesion can be detected at
6 1 ng of ICAM-1 per microtitre well. The promotion of
adhesion by MHM83 is minimal. Since the KIM185 epitope
is not expressed, the mAb has no e¡ect on adhesion (data not
shown). In all cases, adhesion was speci¢c: no adhesion was
detected in wells not coated with ICAM-1. Furthermore, ad-
hesion can be blocked with the mAb MHM24 and, for the KL
transfectants, also with the anti-L2 mAb YFC118 (data not
shown).
3.3. Expression of the mAb 24 epitope on the wild-type
and variant LFA-1
The expression of the epitope for mAb 24 on LFA-1 has
been shown to correlate with a high a⁄nity conformation and
ICAM-1 binding capacity [30]. The epitope was detected on
wild-type LFA-1 transfectants at 37‡C in the presence of Mg/
EGTA, at very low levels at 37‡C, and not at all at 4‡C (Fig.
5), in agreement with previous reports on the property of this
epitope [30]. However, the epitope was detected on the
KLL2NV1 transfectants in the absence of Mg/EGTA, and
not only at 37‡C but also at 4‡C (Fig. 5). Expression of
mAb 24 epitope cannot be detected under the three conditions
on the transfectants expressing the monomeric KL, L2 and
L2NV1 subunits (data not shown).
4. Discussion
How the K and L subunits interact with each other to bind
ligands in a highly regulated fashion is a key question of
integrin-mediated adhesion. In this article, we report the con-
struction of a chimeric L2/L1 integrin subunit, L2NV1, in
which the CRR of L2 is replaced with that of L1, and the
study of L2NV1 on its ability to combine with the KL subunit
to form a variant LFA-1. Since COS-7 cells do not normally
express any subunits of the L2 integrin subfamily, they pro-
vide a suitable cell background for these studies.
Both the KL and L2 subunits can be expressed on COS cells
independently, in agreement with previous reports [31]. In
addition, we showed that they are expressed as monomers.
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Fig. 4. Adhesion of COS-7 transfectants to ICAM-1. Adhesion was
carried out in the absence of activating mAb (a), in the presence of
MEM83 (b) and KIM185 (E). Only the results obtained in the pres-
ence of MEM83 are shown for adhesion with no ICAM-1 coating
are shown. Adhesion was also done in the presence of the blocking
mAb MHM24 at the highest ligand density. Only the results ob-
tained in the presence of MEM83 (U) are shown.
Fig. 3. Immunoprecipitation of surface-labeled LFA-1 subunits.
A: Immunoprecipitates with H52 from L2 (lane b) and L2NV1 (lane
c) transfectants. B: Immunoprecipitates with MHM24 from KL
(lane a), KLL2 (lane b), and KLL2NV1 (lane c) transfectants.
Fig. 2. Flow cytometry analysis of COS-7 transfected with LFA-1
integrin subunits. The expression pro¢les of the epitopes of
YFC118, H52, KIM185 and MHM24 are shown in bold. The back-
ground pro¢les for the rat mAb YFC118 expression were obtained
with the rat mAb YTS191, and those for mouse mAbs, i.e. H52,
KIM185, and MHM24, were obtained with OX33. All ¢rst antibody
staining was done in RPMI-1640 supplemented with 5% fetal calf
serum and 10 mM HEPES, pH 7.5. The positive gates, shown as
horizontal lines, were set to include the brightest 5% of the cells in
the background pro¢les. % positive cells, obtained with the speci¢c
mAbs in the gated region, and their mean £uorescence intensity
(MFI), are indicated above the bar, and an expression index, de-
¢ned as the product of (% positive cells)U(MFI of the positive pop-
ulation), is shown below the bar.
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The epitopes of the mAbs YFC118 [32], H52 [20], and
KIM185 [17,33] are expressed on the monomeric L2 subunit
(Fig. 2). It has been suggested that the HCR of the L2 subunit
does not fold ‘correctly’ in the absence of a proper K subunit
based on the observation that a panel of mAbs, whose epito-
pes map to the HCR, can only recognise the L2 subunit in the
heterodimer state [33]. However, one of these mAbs was
YFC118, which, in our hands, can detect the monomeric L2
subunit. Thus the structural di¡erences between L2 in its
monomeric and heterodimeric states remain to be resolved.
The KL transfectants, in the presence of the stimulating
mAb MEM83 [34], can adhere to ICAM-1 coated surfaces.
This observation is consistent with previous reports that the I-
domain can be expressed independently [4], that it can interact
with ligands [8,35], and that it is properly folded as part of the
KL subunit though proper folding of the L-propeller appears
to require the L2 subunit [36].
On the other hand, there is ample evidence that monomeric
KL and L2 subunits are not expressed on leukocytes. The KL,
KM, nor KX subunits are not detected on leukocytes of LAD
patients, who have defective L2 subunits [14]. Thus, these K
subunits are not expressed as monomers, nor as heterodimers
by combining with another L integrin subunit, such as L1 or
L3, which is expressed on leukocytes [13]. By chemical muta-
genesis, the genes for the KL and L2 subunits have been made
defective in the T lymphoblastoid cell lines Jurkat and SKW3,
respectively [37]. Surface expression of the non-defective sub-
unit could only be detected if the defective counter-subunits
were restored by transfection [37]. Since both the KL and L2
subunits are expressed as monomers on COS cells, there is no
inherent reason why they cannot be expressed on other cells.
We therefore argue that there are certain regulatory mecha-
nisms, yet to be characterised, in leukocytes that prohibit sur-
face expression of the monomers.
It has been reported that COS cell transfectants expressing
LFA-1 are capable of adhesion to ICAM-1 coated surfaces
without stimulation [15,16,31]. In our hands, the adhesion of
LFA-1 transfectants to ICAM-1 requires the presence of acti-
vating mAbs. Since the adhesion properties of LFA-1 may
depend on the cell type on which it is expressed [38], the
discrepancy may therefore be due to the COS cells in di¡erent
laboratories having diverged through passages and providing
di¡erent cellular background for LFA-1 mediated adhesion
activities.
Does the CRR play any part in interacting with the K sub-
unit? The CRR of L3 is not required to combine with the KIIb
subunit to form a truncated integrin heterodimer with ligand
binding activities [39]. However, we should be cautious in
extrapolating this conclusion to other integrins. In this paper,
we have shown that by replacing the CRR of L2 with that of
L1, the resultant chimera is fully capable of combining with
the KL subunit to form a variant LFA-1. We did not address
the question of whether a CRR is required, but we have
demonstrated that the speci¢city of the L2 subunit to combine
with KL does not lie in the CRR.
Why are the transfectants expressing KLL2NV1 more ad-
herent than those expressing wild-type LFA-1? It cannot be
due to expression level, since KLL2NV1 is expressed consis-
tently at a lower level, as judged by the expression of the
YFC118, H52, and MHM24 epitopes, than the wild-type
LFA-1. Results of a representative experiment are shown in
Fig. 2. One emerging view of integrin activation is that resting
state integrins are constrained from binding ligands, and that
activation involves the release of this constraint. The intra-
molecular constraint of the integrins would require inter-sub-
unit and intra-subunit interactions between di¡erent regions
of the heterodimer. The most direct evidence in support of
this model has come from the study of the platelet integrin
KIIbL3 [40]. A putative salt bridge in the cytoplasmic domain
of KIIbL3 was identi¢ed between an Arg of the KIIb subunit
and an Asp of the L3 subunit. It was proposed that this salt
bridge may be a constraining device in maintaining KIIbL3 in
its resting state. This experiment also provided a possible
means, by disrupting the salt bridge, of how a signal originat-
ing inside the cell might propagate through the integrin het-
erodimer to a¡ect the structure of the ligand binding site and
hence the ligand binding activities [41]. There are a number of
mAbs, not only against the L2 integrins [17,33], but also
against the L1 [42^48] and L3 [41,49^51] integrins, that have
been described as activating mAbs by virtue of their ability to
promote ligand binding. In addition, their epitopes often be-
come more accessible upon binding to ligand or activation by
another mAb. The locations of these eptiopes have been de-
scribed for all regions of the extracellular domain: the mAbs
N29 [45] and AP5 [51] have been mapped to the N-terminal
CRR of L1 and L3, respectively, TS2/16 [42] and 12G10 [43]
to the HCR of L1, the HUTS mAbs [44] to the L1 mid-region,
and JB1B [45], 9EG7 [46], and AG89 [47,48] to the L1 CRR,
KIM127 and KIM185 to the L2 CRR [17] and D3GP3 [50]
and the anti-LIBS2 [41] to the L3 CRR. A plausible model,
consistent with the constraint hypothesis, is that the binding
of these mAbs perturbs the intramolecular interaction of the
integrins, thereby releasing them into their activated states.
The locations of their epitopes are not important, activation
is achieved as long as the constraining intramolecular inter-
actions are perturbed. Our results on the KLL2NV1 variant,
which is constitutively active with respect to ICAM-1 binding
and expresses the activation epitope of mAb 24 in the absence
of activating agents, show that the authentic CRR of the L2
subunit is required for the construction of the constraint.
Since the monomeric KL subunit can also be activated to
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Fig. 5. Expression of the epitope of mAb 24. COS-7 transfectants
of wild-type LFA-1 (KLL2) and variant KLL2NV1 were stained for
mAb 24 at 4‡C or 37‡C in RPMI-1640 supplemented with 5% foetal
calf serum and 10 mM HEPES, pH 7.5, or at 37‡C in the same me-
dium with 5 mM MgCl2 and 1 mM EGTA (Mg/EGTA). Second
antibody staining was done in the same medium without Mg/EGTA
at 4‡C. % positive cells, their MFI and expression indices are shown
similarly as in Fig. 2.
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bind ICAM-1, one possible interpretation of these results is
that the L2 subunit is purely regulatory in restricting the bind-
ing activity of wild-type LFA-1. This restriction is lost in
KLL2NV1 and the KL subunit is freed to bind ICAM-1. How-
ever, this description cannot be complete. The L2 subunit
must also contribute to binding because several laboratory
constructed L2 mutants have been shown to form LFA-1 het-
erodimers which cannot bind ligands [15,16].
The immediate extensions of this work are to study the
adhesion properties of the KLL2NV1 to other ligands for
LFA-1, i.e. ICAM-2 and ICAM-3, and to determine if
L2NV1 can form heterodimers with the KM and KX subunits,
and if the resultant heterodimers can bind ligands. We also
plan to construct chimeras of other regions, such as the mid-
region, of the integrin L subunit, and chimeras involving the
exchange of smaller regions. Ultimately, we aim to map the
residues in the integrins which are involved in heterodimer
formation, ligand binding, and regulation of their adhesion
activities.
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